Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Neoplasms 3Carcinoma, Renal Cell 3Kidney Neoplasms 2Glioma 2Disease Progression 2Carcinoma, Medullary 2Brain Neoplasms 2Waldenstrom Macroglobulinemia 1Thyroid Neoplasms 1Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Peritoneal Neoplasms 1Ovarian Neoplasms 1Oligodendroglioma 1Mycosis Fungoides 1Multiple Endocrine Neoplasia Type 2b 1Multiple Endocrine Neoplasia Type 2a 1Multiple Endocrine Neoplasia 1Lymphoproliferative Disorders 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, Extranodal NK-T-Cell 1Lymphoma, B-Cell, Marginal Zone 1Lymphoma 1

Interventions

vandetanib 1gallium Ga 68 dotatate 1fluorodopa F 18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Multiple Endocrine Neoplasia × vandetanib × Clear all
NCT00514046 2020-12-22

Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer

National Institutes of Health Clinical Center (CC)

Phase 1/2 Completed
17 enrolled 25 charts
Endocrine

Multiple Endocrine Neoplasia, Carcinoma, Medullary, Multiple Endocrine Neoplasia Type 2a, Multiple Endocrine Neoplasia Type 2b

Data powered by HemOnc (CC BY 4.0) Colophon âš¡